Significantly Delayed Development of Polyarthritis with Active Tenosynovitis after Possible Temporary Neutropenic Immune-Related Adverse Events Caused by Atezolizumab Treatment: A Novel Case Report

Table 1

Laboratory data on day 645.

	Value on day 645	Normal range
IgA (mg/dL)	453	93–393
IgG (mg/dL)	2510	861–1747
IgM (mg/dL)	186	33–183
Complement C3 (mg/dL)	180	73–138
Complement C4 (mg/dL)	46	11–31
50% hemolytic complement activity (U/mL)	90.7	31.6–57.6
Anti-nuclear antibody (fold)	40.0	<40
SS-A antibody (U/mL)	>2200	<10
PR3-ANCA (U/mL)	15.0	<3.5
MMP-3 (ng/mL)	430.5	36.9–121.0
C-reactive protein (mg/dL)	3.08	0–0.14
MPO-ANCA (U/mL)	<0.3	<3.5
Rheumatoid factor (IU/mL)	<4.5	≤15
Uric acid (mg/dL)	5.7	3.7–7.8
Anti-citrullinated peptide antibody	Negative	Negative